Somewhat Positive Press Coverage Somewhat Unlikely to Impact Akebia Therapeutics (AKBA) Stock Price

News headlines about Akebia Therapeutics (NASDAQ:AKBA) have been trending somewhat positive on Saturday, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akebia Therapeutics earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.3255494523475 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the headlines that may have impacted Accern’s rankings:

Several brokerages have weighed in on AKBA. Mizuho reaffirmed a “buy” rating and set a $24.00 target price on shares of Akebia Therapeutics in a research note on Thursday. Royal Bank of Canada reaffirmed a “hold” rating and set a $17.00 target price on shares of Akebia Therapeutics in a research note on Thursday, November 2nd. Zacks Investment Research lowered shares of Akebia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. ValuEngine raised shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, BidaskClub raised shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Akebia Therapeutics currently has a consensus rating of “Buy” and an average price target of $20.63.

Akebia Therapeutics (NASDAQ AKBA) traded up $0.39 during midday trading on Friday, hitting $15.49. 674,900 shares of the stock traded hands, compared to its average volume of 515,651. Akebia Therapeutics has a twelve month low of $7.78 and a twelve month high of $20.25.

Akebia Therapeutics (NASDAQ:AKBA) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.07. Akebia Therapeutics had a negative net margin of 137.80% and a negative return on equity of 198.85%. The business had revenue of $41.28 million during the quarter, compared to analyst estimates of $34.00 million. sell-side analysts expect that Akebia Therapeutics will post -3.03 EPS for the current year.

In other news, SVP Michel Dahan sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $19.30, for a total value of $96,500.00. Following the completion of the transaction, the senior vice president now owns 97,224 shares of the company’s stock, valued at $1,876,423.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last three months, insiders sold 12,586 shares of company stock valued at $222,289. Insiders own 7.95% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Akebia Therapeutics (AKBA) Stock Price” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/11/11/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-akebia-therapeutics-akba-stock-price.html.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Insider Buying and Selling by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply